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A B S T R A C T
Background: Enterococci are a clinically signiﬁcant cause of bloodstream infections (BSI), particularly in
the nosocomial setting. The purpose of this study was to characterize the incidence, risk factors for
acquisition, microbiological characteristics and mortality of enterococcal BSI within the well-deﬁned
population of a large Canadian health region.
Methods: Surveillance for all episodes of enterococcal BSI occurring among residents of the Calgary
Health Zone (population 1.2 million) between 2000 and 2008 was conducted using an electronic
surveillance system. Clinical features, microbiology, and outcomes were obtained.
Results: A total of 710 incident episodes of enterococcal BSI were identiﬁed for an annual incidence of 6.9
episodes per 100,000; the incidences of E. faecalis and E. faecium BSI were 4.5, and 1.6 per 100,000,
respectively. Enterococcus faecalis infections were associated with a urinary focus, genitourinary
malignancy, and abnormal genitourinary anatomy. E. faecium infections were associated with a
gastrointestinal focus. Resistance to ampicillin, vancomycin and ciproﬂoxacin was higher in E. faecium
infection. The overall case fatality rate was 22.8%, and was higher for E. faecium infection.
Conclusions: This is the second population-based study to assess the risk factors for enterococcal BSI and
compare the characteristics of infection with E. faecalis and E. faecium. Results suggest that BSI with
E. faecalis and E. faecium should be regarded as two clinically different entities with unique sets of risk
factors and microbiologic characteristics.
 2014 The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-
nc-nd/3.0/).
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jou r nal h o mep ag e: w ww .e lsev ier . co m / loc ate / i j id1. Introduction
Enterococcus species are a frequent cause of blood stream
infections (BSI) in North America1–6. In-hospital mortality
associated with enterococcal BSI has been estimated between
25-50%7–12, leading to the recognition of the Enterococcus species
as formidable pathogens. The treatment of enterococcal BSI isAbbreviations: BSI, bloodstream infection(s); CSI, Charlson Severity Index; CHZ,
Calgary Health Zone; GI, gastrointestinal; PUD, peptic ulcer disease.
* Corresponding author. Department of Medicine, Alberta Health Services, 3330
Hospital Drive NW, Calgary Alberta, Canada, T2N 4N1. Tel.: +1/403/210-7913;
fax: +1/403/270-2272.
E-mail address: mdparkin@ucalgary.ca (M.D. Parkins).
* These authors contributed equally to this work
http://dx.doi.org/10.1016/j.ijid.2014.02.012
1201-9712/ 2014 The Authors. Published by Elsevier Ltd on behalf of International So
license (http://creativecommons.org/licenses/by-nc-nd/3.0/).complicated by high rates of antimicrobial resistance, with all
enterococci being inherently resistant to cephalosporins and an
increasing prevalence of vancomycin and ampicillin resistance
being encountered in many health regions. Resistance to
aminoglycosides as synergistic agents has also become more
prevalent9,13.
The two most ubiquitous Enterococcus species, E. faecalis and
E. faecium, are often considered to be similar entities and treated as
such. However, E. faecium has been associated with BSI in a more
severely ill subset of patients, has higher rates of antibiotic
resistance, and has been associated with higher mortality than
E. faecalis BSI7,8,14,15.
Enterococcal BSI are often associated with a urinary tract, intra-
abdominal, or endovascular source3,7,14,16–21. Older age, male
gender, liver disease, renal impairment, diabetes, hematologicciety for Infectious Diseases. This is an open access article under the CC BY-NC-ND
E.O. Billington et al. / International Journal of Infectious Diseases 26 (2014) 76–82 77transplant, malignancy, and prior treatment with antibiotics have
all been associated with the acquisition of BSI in other non-selected
observational cohort studies7,8,14,20,21. However, the data from
these studies is mainly derived from selected tertiary care
hospitals, subjecting these reports to referral biases1,2,5,7,14,17–21.
This type of bias can be overcome by conducting population-based
studies which allows investigators to minimize selection biases by
studying a well-deﬁned geographic region22. The purpose of this
study was to characterize the incidence, risk factors for acquisition,
microbiological characteristics and clinical outcomes of entero-
coccal BSI within the well-deﬁned population of a large Canadian
health region, while also comparing E. faecalis to E. faecium BSI.
2. Methods
2.1. Study Population
Our study population involved the Calgary Health Zone (CHZ).
This healthcare region provides medical and surgical care to the
residents of Calgary, Airdrie, and a large surrounding catchment
area (total population 1.2 million) in the province of Alberta,
Canada. Only patients requiring acute liver, heart, or lung
transplantation surgery are routinely referred elsewhere. All
persons who resided in the CHZ and developed enterococcal BSI
between 2000 and 2008 were included in the study. Approval was
obtained from Conjoint Health Research Ethics Board at the
University of Calgary and CHZ prior to commencement of this
study.
2.2. Study Protocol
We employed a retrospective, population-based surveillance
cohort design. Surveillance for enterococcal infections was
performed using the Electronic Surveillance System23. This system
utilizes data from regional laboratory, hospital, and vital statistics
information systems with application of clinically validated
algorithms to identify and classify patients with incident BSI. All
patients with blood samples submitted for culture from hospitals,
nursing homes, and clinics in the CHZ are identiﬁed. Further
clinical and outcome data including demographics, pre-existing
co-morbidities, hospital admission, and mortality are obtained on
patients admitted to any of the 4 major acute care hospitals
(representing >95% of hospital admissions in the CHZ). Informa-
tion regarding co-morbidities was established from ICD-9 and ICD-
10 codes24.
2.3. Deﬁnitions
Enterococcal BSI was deﬁned by its isolation from 1 or more sets
of aseptically obtained blood culture bottles and cultured using the
BacT/Alert automated instrument (Organon Teknika, Durham, NC,
USA). Clinical isolates were cultured, conﬁrmed as Enterococcus,
further speciated into E. faecium, E. faecalis or alternate species and
then tested for antimicrobial susceptibility by standard Clinical
and Laboratory Standards Institute (CLSI) techniques25. Entero-
coccal cultures obtained from non-blood sites within 48 hours of
the index incident blood culture draw, as well as clinical
assessment of the patient, was evaluated to determine the primary
source of infection. An incident case in a CHZ resident was deﬁned
as the ﬁrst new isolation of Enterococcus from the blood; repeated
isolation of the same species of Enterococcus within 365 days of the
ﬁrst isolation was deemed to represent the same incident
infection. A single incident event was also considered if more
than one species of Enterococcus was isolated from the same blood
culture sample or if two samples were collected within 48 h of one
another that showed the same species. Polymicrobial bacteraemiawas deﬁned as an episode with more than one clinically important
bacterial isolate detected within 48 hours of incident draw.
Residency status and population statistics were established using
the 2003 boundaries of the CHZ26.
Nosocomial acquired BSI were those in which the ﬁrst positive
culture was obtained 48 hours or more after hospital admission or
within 48 hours of discharge from the hospital. Community-onset
BSI were those in which the ﬁrst positive culture was obtained less
than 48 hours after hospital admission or more than 48 hours after
discharge from hospital. Community-onset BSI were further
classiﬁed as either health-care associated or community-acquired
as previously described23
2.4. Statistical Analysis
Analysis was performed using Stata version 11.0 (Stata Corp,
College Station, Tex). Non-normally distributed variables were
reported as medians with interquartile ranges (IQRs) and
compared using the rank-sum test for pairs or median test for
groups. Differences in proportions among categorical data were
assessed using the Fisher’s exact test for pairwise comparisons and
the chi2 test for multiple groups. Incidence of enterococcal BSI was
calculated by dividing the number of incident cases by the total
population of the region. Population-based risk factors for
developing enterococcal BSI were quantiﬁed by dividing the
incidence of these infections among those with a given factor by
those without the factor. Regional demographic data were used to
determine the population at risk for assessment of age and
gender27. To determine risk factors, the population at risk was
ascertained using local patient registry data, regional or Canadian
survey data, or published North American epidemiology studies28–
39. Risks were expressed as incident rate ratios and reported with
95% conﬁdence intervals. A logistic regression model was
developed to assess independent factors associated with in-
hospital death. Factors found to be signiﬁcant at the P<0.1 level in
univariate analysis were included in the initial model, and
backwards stepwise variable elimination was then performed to
develop the ﬁnal model. Model calibration was assessed using the
Hosmer-Lemeshow goodness-of-ﬁt test, and discrimination was
assessed using the area under the receiver operating characteristic
curve. For all statistical comparisons a P value of less than 0.05 was
deemed statistically signiﬁcant.
3. Results
A total of 710 enterococcal BSI occurred in 695 CHZ residents in
our 9-year study period. Of the 695 patients who developed
enterococcal BSI during the study period, 7 had two episodes >365
days apart, 1 had three separate infections >365 days apart, and 6
had two infections >48 h but <365 days apart with two different
species of Enterococcus. Eleven patients had an infection in which
two different species of Enterococcus were isolated within 48 h of
each other.
Basic patient demographic data (age, gender and residency),
acquisition data (nosocomial, health-care associated, community
acquired), and 30-day mortality were available for all 710 incident
episodes of enterococcal BSI. Of these cases, 654 (92%) were
admitted to one of the 4 major acute care hospitals in the CHZ.
Additional detailed clinical data regarding co-morbidities were
available for 653 of these patients.
For the 710 episodes of enterococcal BSI, speciation was
available in 667 (94%). The most commonly isolated enterococcal
species in incident BSI was E. faecalis, which comprised 467 (70%)
of isolates. Enterococcus faecium was the second most common
species, comprising 169 (25%) of isolates. Of the remaining 31 (4%)
isolates, 8 were E. gallinarium, 8 were E. cassiﬂavus, 2 were
Figure 1. Incidence of bloodstream infection due to various Enterococcus species in
the Calgary Health Zone from 2000 to 2008.
Figure 3. Age and gender distribution of enterococcal bloodstream infection in the
Calgary Health Zone (M, male; F = female).
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species of Enterococcus but were not classiﬁed in terms of causative
species.
3.1. Incidence and Risk Factors
The annual incidence of enterococcal BSI was 6.9 per 100,000.
The overall incidence of E. faecalis BSI was 4.5 per 100,000, and was
1.6 per 100,000 for E. faecium (Figure 1).
Of the 710 enterococcal BSI, 338 (48%) were hospital-acquired,
228 (32%) were health-care associated, and 144 (20%) were
community-acquired. Modes of acquisition ﬂuctuated over the
9-year period, but no trend was evident (Figure 2).
The median age of patients at time of Enterococcus spp. BSI was
68.4 years (IQR, 51.3-78.2). The age distribution was bimodal, with
peak incidences in the neonatal and elderly populations (Figure 3).
Being male (467/709, 66%, RR, 1.9; 95% CI, 1.7-2.3; P <0.0001) or
70 years of age (327/710, 46%, RR, 12.2; 95% CI, 10.5-14.2,
P<0.0001) were both associated with increased risk of acquiring
enterococcal BSI.
Detailed clinical data regarding patient comorbidities was
available for 653 (92%) of the enterococcal BSI (Table 1). Risk
factors for acquiring enterococcal BSI (Table 2), included any type
of cancer; particularly gastrointestinal, genitourinary, and hema-
tologic primary malignancies. Chronic kidney disease was alsoFigure 2. Mode of acquisition of enterococcal bacteremia in the Calgary Health Zone
from 2000 to 2008 (CA, community-acquired; HCA, healthcare-associated; NA,
nosocomially-acquired).associated with increased risk of acquisition, especially patients
receiving renal replacement therapy. Peptic ulcer disease, inﬂam-
matory bowel disease, diabetes, heart disease, stroke, rheumatoid
arthritis and hypertension were also risk factors. HIV infection was
associated with an increased risk of acquiring E. faecium BSI (RR
2.4; 95% CI 15-12.7; P= 0.01).
Patient characteristics differed between individuals with
E. faecalis and E. faecium BSI. Incident E. faecium infections were
more often nosocomial than E. faecalis infections (70% vs 41%,
P<0.0001). Patients with E. faecium BSI were more likely to have a
Charlson Severity Index (CSI) of 5 or greater than patients with
E. faecalis BSI (25% vs 18%, P= 0.04). Individual comorbidities of
chronic liver disease, hematologic malignancy and peptic ulcer
disease (PUD) were signiﬁcantly more common in patients who
developed E. faecium BSI, whereas genitourinary malignancy,
dementia, hypertension and abnormal genitourinary anatomy
were more common with E. faecalis BSI (Table 1).
3.2. Microbiology
A total of 184 (26%) of incident infections were polymicrobial.
Escherichia coli (43 isolates, 6%), Staphylococcus aureus (25 isolates,
4%), Klebsiella pneumoniae (20 isolates, 3%) and coagulase negative
staphylococci (19 isolates, 3%) were the most common pathogens
associated with polymicrobial infection. There was no difference in
the frequency of polymicrobial infection between E. faecalis and
incident E. faecium, respectively [28% (102/361)] [33% (42/128)],
p=0.37.
Data regarding resistance to antimicrobials was sought for all
721 enterococcal isolates associated with incident infection (710
incident infections, 11 involved two different species of Enterococ-
cus). Resistance data was available for 677 (95%) of isolates.
Enterococcus faecalis isolates had lower resistance rates than
E. faecium to ampicillin, vancomycin, and ciproﬂoxacin, but
resistance to high-level gentamicin was similar (Table 3).
Sources of infection were available for 655 (92%) of incident
infections (Table 4). No source was identiﬁed for 142 (22%) of these
incident infections, and these were assumed to be primary BSI. A
genitourinary focus was more common in E. faecalis than E. faecium
BSI (37% vs 9%, P<0.0001), whereas an intra-abdominal (61% vs
30%; P<0.0001) or pulmonary (10% vs 5%; P=0.03) focus was more
common in E. faecium. Polymicrobial infections were more likely to
come from a gastrointestinal source relative to all other sources
(RR 1.55 (CI 1.2-2.0), p=0.001)
3.3. Outcomes
Among the 654 patients who were admitted to hospital, median
hospital length of stay was 20.0 days (IQR, 8.2-49.1). Length of stay
Table 1
Baseline characteristics of patients who had Enterococcus faecium and Enterococcus faecalis blood stream infections
Patient characteristic All E. faecalis E. faecium p-Value
Age, years, median (IQR) 68 (51–78) 69 (50–79) 67 (54–77) NS
Gender, % male 66 66 67 NS
Charlson severity index, median (IQR) 2 (0–4) 2 (0–4) 2 (1–4) 0.002
Comorbidities, n (%)
Any malignancy 179 (27) 108 (25) 54 (34) NS
Malignancy, GI primary 68 (10) 35 (8) 21 (13) NS
Malignancy, urologic primary 56 (9) 45 (10) 8 (5) 0.05
Hematologic malignancy 39 (6) 38 (9) 23 (14) <0.0001
Malignancy, metastatic 60 (9) 38 (9) 14 (9) NS
Inﬂammatory bowel disease 14 (2) 8 (2) 4 (3) NS
Peptic ulcer disease 52 (8) 27 (6) 22 (14) 0.006
Chronic renal disease, all 136 (21) 97 (23) 32 (20) NS
Chronic renal disease, dialysis 26 (4) 18 (4) 5 (3) NS
Diabetes 141 (22) 96 (22) 32 (20) NS
Heart disease 273 (42) 178 (41) 69 (43) NS
Stroke 42 (6) 30 (7) 9 (6) NS
COPD 49 (8) 31 (7) 12 (8) NS
IQR, interquartile range; NS, non-signiﬁcant; GI, gastrointestinal or hepatobiliary; COPD, chronic obstructive pulmonary disease; RA, rheumatoid arthritis.
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to E. faecalis BSI (LOS, 32.1(IQR 15.9-65.0) vs 17.8 (IQR 7.0-45.0),
P <0.0001).
The case-fatality for incident enterococcal BSI was 162/710
(23%). The annual incident mortality was 1.6 per 100,000 persons.
In univariate analysis (Table 5), mortality was associated with
hospital acquisition and an increasing CSI. GI malignancies (28/68,
41%, RR 1.93, P=0.005), and metastatic malignancies (25/60, 42%,
RR 1.93, P=0.009) were associated with death. Other risk factors for
death were heart disease (77/273, 29%, RR 1.49, P=0.002) and
stroke (13/42, 31%, RR 1.35, P=0.035). However, having abnormal
urological anatomy (10/81, 12%, RR 0.5, P=0.025) was associated
with a decreased risk of mortality. Similarly resistance to
ampicillin, ciproﬂoxacin and high-level gentamicin were all
associated with higher case-fatality rates than sensitive isolates.
Pulmonary (53% mortality) and gastrointestinal (31% mortality),
sources associated with the highest case-fatality rates.
The case-fatality rate for E. faecalis infection was signiﬁcantly
lower than that for E. faecium infection (17% vs 30%; P<0.0001).
Mortality in individuals with E. faecalis BSI were more commonly
associated with pulmonary focus (RR 2.75 (CI 1.3-3.8), malignancy
with either GI focus (2.21 (CI 1.3-3.7) or metastatic involvement
(RR 2.3 (CI 1.3-3.8), nosocomial acquisition (RR 1.77 (CI 1.2-2.7),
ciproﬂoxacin resistance (RR 1.7 (CI 1.1-2.5) or co-morbiditiesTable 2
Risk of enterococcal bacteremia associated with selected underlying conditions
Risk factor Age group, yearsa
Bone marrow transplant All 
Solid organ transplant 20+ 
Any malignancy All 
Hematological malignancy All 
GI malignancy All 
Urological malignancy All 
Chronic kidney disease, requiring dialysis All 
Chronic kidney disease, all 18+ 
Heart disease 12+ 
Diabetes 12+ 
Stroke 12+ 
Hypertension 12+ 
COPD 35+ 
Inﬂammatory bowel disease All 
Peptic ulcer disease 12+ 
Dementia 35+ 
RA 18+ 
HIV All 
RR, rate ratio; CI, conﬁdence interval; GI, gastrointestinal or hepatobiliary; COPD, chro
a Number of cases in age groups: all n = 653; 12+ n = 606; 18+ n = 605, 20+ n = 604, 3including dementia (RR 1.95 (CI 1.1-5.5) and prior cardiac disease
(RR 1.63 (CI 1.1-2.5). In those individuals with E. faecium BSI,
mortality was more commonly associated with antimicrobial
resistance to ampicillin (RR 4.64 (CI 1.8-12.2), ciproﬂoxacin (RR
3.24 (CI 1.1-9.7) and vancomycin (RR 2.21 (CI 1.3-3.7) or
nosocomial acquisition (RR 1.28 (CI 1.1-1.6).
Multivariate logistic regression (Table 6) was used to assess risk
factors for death in all patients with Enterococcus spp BSI and had
both good discrimination (area under receiver operating charac-
teristic 0.75) and calibration (goodness-of-ﬁt test, P=0.4). The ﬁnal
model included CSI, solid organ transplant, E. faecalis isolates,
pulmonary infections, polymicrobial infections, and nosocomial
acquired infections.
4. Discussion
In our large Canadian health region, we determined that the
annual incidence of enterococcal BSI is 6.9/100 000 per year. Other
studies within the population of the CHZ have found bacteremia
due to Escherichia coli (30/100 000 per year) and Staphylococcus
aureus (28/100 000 per year) to be more common than
Enterococcus, but the incidence of Streptococcus milleri (8.7/100
000 per year) and Klebsiella pneumoniae (7.1/100 000 per year) are
comparable40–43.n (%) RR (95% CI) p-Value
9 (1) 349.4 (159.0–667.4) <0.0001
17 (3) 28.9 (16.7–46.7) <0.0001
140 (21) 11.9 (9.8–14.4) <0.0001
39 (6) 33.4 (23.5–46.1) <0.0001
68 (10) 28.2 (21.6–36.3) <0.0001
56 (9) 17.6 (13.1–23.1) <0.0001
26 (4) 44.5 (28.9–65.9) <0.0001
131 (20) 3.6 (2.9–4.3) <0.0001
250 (38) 16.9 (14.3–19.9) <0.0001
141 (22) 7.7 (6.3–9.3) <0.0001
41 (6) 7.2 (5.1–9.9) <0.0001
175 (27) 2.9 (2.4–3.5) <0.0001
49 (8) 0.9 (0.6–1.2) 0.40
14 (2) 4.7 (2.6–8.0) 0.001
52 (8) 3.0 (2.2–4.0) 0.0001
36 (6) 4.2 (3.0–6.0) <0.0001
15 (2) 3.9 (2.2–6.5) 0.02
2 (<1) 3.1 (0.4–11.1) 0.65
nic obstructive pulmonary disease; RA, rheumatoid arthritis.
5+ n = 580.
Table 3
Resistance of enterococcal bloodstream isolates to selected antibiotics
Antibiotic All isolates (n = 677)
n (% resistant)
E. faecalis isolates (n = 470)
n (% resistant)
E. faecium isolates (n = 174)
n (% resistant)
p-Value
Ampicillin 126 (19) 2 (0.4) 122 (70) <0.0001
Ciproﬂoxacin 274 (40) 133 (28) 137 (79) <0.0001
Vancomycin 28 (4) 6 (1) 12 (7) 0.001
Gentamicin (synergistic dose) 153 (23) 117 (25) 35 (20) NS
NS, non-signiﬁcant.
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cal BSI was recently reported by Pinholt and colleagues44. Our
study is congruent with the Danish study with respect to 30-day
mortality rates, commonest sites of infection for E. faecalis and
E. faecium, rates of ampicillin and vancomycin resistance, and
increased risk for mortality with nosocomial acquisition. However,
the incidence of enterococcal infection was strikingly different
(6.9/100 000 vs 19.6/100 000). In addition, high-level gentamicin
resistance rates for E. faecium in the Danish study were
considerably higher than in our study (64.4% vs 20%). Possible
explanations for these results include differences in clinical
practices, laboratory protocols, and antibiotic stewardship prac-
tices. Further, Laupland et al.45 previously indicated that older age
and male sex were risk factors for acquiring BSI. This study
suggested that countries with predominantly older males could
inﬂuence incidence rates, and thus could explain the inherent
difference in incidence between our report and the Danish study.
Our results conﬁrm historically identiﬁed risk factors for
enterococcal BSI from non-population based studies, such as older
age, male gender, renal impairment, liver disease, solid organ and
bone marrow transplant7,8,14,19,20. In addition, we have also found
that hematologic, intra-abdominal, gastrointestinal primary ma-
lignancies, and metastatic disease are associated with a signiﬁ-
cantly higher incidence of enterococcal BSI than the general
population.
The majority of enterococcal BSI in our study was from an intra-
abdominal, urinary, or endovascular source, in keeping with prior
observations3,7,14,17–21,44,46. We also reported a high proportion of
pulmonary sources. Previous studies have suggested that pneu-
monia due to Enterococcus may be found in patients receiving
enteral nutrition, particularly those on broad-spectrum antibiotics,
due to colonization of the oropharynx16. These factors may have
contributed to pulmonary enterococcal infection in our study,
although we were unable to determine if these characteristics
applied to our patients. Twenty-ﬁve percent of enterococcal BSIs
acquired in the nosocomial setting are due to E. faecium,
comparable to 14-37% in prior studies2,5,7,10,14,15.
We report higher vancomycin resistance rates than previously
suggested in CHZ in 1999 (1.3%)5, but similar to a more recentTable 4
Source of enterococcal bacteremia, based on cultures from other body sites and
clinical focus of infection
Source All isolates
n (%)
E. faecalis
n (%)
E. faecium
n (%)
p-Value
Primary BSI 142 (22) 100 (23) 32 (20) NS
GI 211 (41) 99 (30) 77 (61) <0.0001
Urologic 139 (27) 122 (36) 12 (9) <0.0001
Endovascular 78 (15) 57 (17) 13 (10) NS
Pulmonary 34 (7) 16 (5) 13 (10) 0.03
Skin and soft tissue 24 (5) 15 (5) 8 (6) NS
Bone and joint 17 (3) 13 (4) 4 (3) NS
Reproductive 6 (1) 6 (2) 0 (0) NS
CNS 3 (1) 2 (1) 0 (0) NS
EENT 1 (<1) 1 (<1) 0 (0) NS
BSI, bloodstream infection; NS, non-signiﬁcant; GI, gastrointestinal or hepatobili-
ary; CNS, central nervous system; EENT, eyes, ears, nose, and throat.Canadian study by Adam et al (4.6%)6. Our rates of vancomycin
resistance were low compared to reports from the United
Kingdom13, and signiﬁcantly lower than what has been reported
in India and the United States, where >10% of E. faecalis isolates
and >80% of E. faecium isolates are resistant to vancomycin1,5,15,47.
We found lower rates of ampicillin resistance than reported in a
prior Canadian study from 199448, but our rates of ampicillin
resistance were similar to reports from the United States in 19995.
Our rates of high-level gentamicin resistance are comparable to the
United States, United Kingdom, and New Zealand1,5,7,13,14.
The observed case-fatality rate of 23%, consistent with the Danish
study of Pinholt et al was low compared to prior reports7–12. This
may be a reﬂection of selection bias of these non-population based
studies owing to referral from specialty centres, geographic location,
and case mixes that are inherent in other studies. Signiﬁcantly
higher mortality was associated with nosocomial infections
compared to community-acquired infections as hospital-based
patients likely carry more co-morbidities7,10. Patients with higher
Charlson Severity Index (CSI), gastrointestinal and metastatic
malignancy, diabetes, inﬂammatory bowel disease, and heart
disease were also associated with higher mortality risk, which is
similar to earlier reports7,12,15. Higher mortality was associated with
ampicillin, ciproﬂoxacin, and gentamicin resistant strains, a ﬁnding
consistent with published studies7,10. Risks for mortality differed
between E. facealis BSI and E. faecium. While our data overall did not
show higher mortality rates with vancomycin resistant strains, we
did note increased risk in E. faecium BSI.
The present study has limitations that require acknowledge-
ment. Due to its retrospective nature, data requiring patient
characteristics, comorbidities, and information regarding clinical
focus of BSI was reliant upon review of patient records rather than an
interview or clinical examination at the time of infection. We were
unable to distinguish true infectious endocarditis cases from other
endovascular infections such as line infections, and as such did not
speciﬁcally analyze these factors. Since data were processed from
ICD-9 and ICD-10 codes, several comorbidities may have been
underreported and infections deemed to be ‘‘primary BSIs’’ due to
lack of an overt source may have actually had an infectious focus.
Calculations of risk factors for enterococcal BSIs were crude, as we
utilized population-based studies to estimate the prevalence of
many disease states within the CHZ. Furthermore, we were not able
to assess population level independent risk factors for the
acquisition of enterococcal BSI owing the use of this crude, unlinked
data. This limitation is nearly universal to all population-based
observational designs. We did not have data regarding prior or
present antibiotic treatment of our patients, which could elucidate
the risk associated with prior antibiotic also determine what
proportion of patients with enterococcal BSI were treated appropri-
ately while awaiting cultures and sensitivities. Finally, it is possible
that our study underestimates the incidence of enterococcal BSI, as it
only assesses blood samples submitted for culture, and therefore
excluded any patients who had enterococcal BSI during the study
periods but did not have blood samples submitted for culture.
Enterococci remain an important cause of BSI. Using population
based data we have been able to deﬁne the incidence, risk factors
for and outcomes in a general North American patient population.
Table 5
Univariate analysis of risk factors for 30-day mortality associated with Enterococcus spp bacteremia
Patient characteristic Mortality with factor (%) Mortality without factor (%) RR (95% CI) p-Value
Age 70 years 77/327 (24) 85/383 (22) 1.06 (0.77–1.46) 0.35
Male gender 106/467 (23) 56/242 (23) 0.98 (0.79–1.21) 0.87
Charlson severity index
0 19/183 (10) 133/470 (28) 0.37 (0.22–0.59) <0.0001
1–2 38/201 (19) 114/452 (25) 0.75 (0.52–1.06) 0.1
3–4 46/139 (33) 106/514 (21) 1.60 (1.12–2.25) 0.008
>4 49/130 (38) 103/523 (20) 1.91 (1.35–2.68) 0.0002
Comorbidities
Any solid malignancy 41/140 (29) 112/513 (22) 1.34 (0.92–1.91) 0.10
GI malignancy 28/68 (41) 125/585 (21) 1.93 (1.19–3.03) 0.005
Urologic malignancy 14/56 (25) 139/598 (23) 1.08 (0.55–1.96) 0.79
Hematologic malignancy 10/39 (26) 143/614 (23) 1.10 (0.49–2.25) 0.76
Metastatic malignancy 25/60 (42) 128/593 (22) 1.93 (1.16–3.13) 0.009
Inﬂammatory bowel disease 3/14 (21) 150/639 (23) 0.91 (0.17–3.27) 0.94
Peptic ulcer disease 21/52 (40) 132/601 (22) 1.84 (1.05–3.11) 0.024
CKD, all 33/136 (24) 120/517 (23) 1.05 (0.69–1.54) 0.80
CKD, dialysis 8/26 (31) 145/627 (23) 1.38 (0.54–3.16) 0.40
Diabetes 36/141 (26) 117/512 (23) 1.12 (0.75–1.62) 0.55
Heart disease 79/273 (29) 74/380 (19) 1.49 (1.14–1.92) 0.002
Stroke 13/42 (31) 140/611 (23) 1.35 (0.67–2.57) 0.035
COPD 14/49 (29) 139/604 (23) 1.24 (0.63–2.29) 0.47
Dementia 11/33 (33) 142/620 (23) 1.46 (0.66–2.95) 0.29
HIV 1/2 (50) 152/651 (23) 2.14 (0.04–41.14) 0.56
Hypertension 42/179 (23) 111/474 (23) 1.02 (0.70–1.41) 0.98
Rheumatic disease 5/15 (33) 148/638 (23) 1.44 (0.41–4.16) 0.048
Underweight 10/29 (34) 143/624 (23) 1.5 (0.65–3.18) 0.27
Heavy alcohol use 14/44 (32) 139/609 (23) 1.39 (0.71–2.59) 0.28
Chronic liver disease 17/50 (34) 136/603 (23) 1.51 (0.82–2.66) 0.15
Solid organ transplant 1/19 (5) 152/634 (24) 0.22 (0.005–0.14) 0.09
Bone marrow transplant 3/9 (33) 150/644 (23) 1.43 (0.25–5.73) 0.58
Ileostomy or colostomy 3/18 (17) 150/635 (24) 0.71 (0.13–2.42) 0.62
Abnormal urologic anatomy 10/81 (12) 143/573 (25) 0.5 (0.23–0.96) 0.025
Mode of acquisition
Nosocomial acquisition 106/339 (31) 56/371 (15) 2.07 (1.65–2.58) <0.0001
Healthcare-associated 41/227 (18) 121/483 (25) 0.72 (0.50–1.01) 0.05
Community acquisition 15/144 (10) 147/566 (26) 0.40 (0.22–0.68) 0.0002
Enterococcal species
E. faecalis 78/467 (17) 61/200 (31) 0.55 (0.43–0.70) <0.0001
E. faecium 51/169 (30) 88/498 (18) 1.71 (1.22–2.35) 0.001
Other 10/31 (32) 129/636 (20) 1.59 (0.70–3.33) 0.21
Antimicrobial resistance
Ampicillin 45/122 (37) 94/545 (17) 2.14 (1.48–3.03) <0.0001
Ciproﬂoxacin 81/269 (30) 56/385 (15) 2.07 (1.59–2.66) <0.0001
Vancomycin 9/27 (33) 131/640 (20) 1.63 (0.67–3.57) 0.22
High-level gentamicin 41/149 (28) 98/517 (19) 1.45 (1.00–2.06) 0.04
Polymicrobial infection 51/184 (28) 111/526 (21) 1.31 (0.94–1.80) 0.091
Source of infection
Primary bacteremia 32/142 (23) 121/513 (24) 0.96 (0.63–1.41) 0.80
GI 66/211 (31) 87/444 (20) 1.60 (1.19–2.11) 0.0014
Urologic 20/139 (14) 133/516 (26) 0.56 (0.33–0.90) 0.01
Endovascular 12/78 (15) 141/577 (24) 0.63 (0.31–1.16) 0.13
Pulmonary 18/34 (53) 135/621 (22) 2.44 (1.29–4.34) 0.004
Skin and soft tissue 4/24 (17) 149/631 (24) 0.71 (0.18–2.05) 0.50
Bone and joint 1/17 (6) 152/638 (24) 0.25 (0.01–1.58) 0.13
Reproductive 0/6 (0) 153/649 (24) 0 (0–3.60) 0.28
CNS 0/3 (0) 152/652 (23) 0 (0–10.3) 0.53
EENT 0/1 (0) 153/654 (23) 0 (0–166.7) 0.81
RR, relative risk; CI, conﬁdence interval; GI, gastrointestinal or hepatobiliary; CKD, chronic kidney disease; COPD, chronic obstructive pulmonary disease; CNS, central
nervous system; EENT, eyes, ears, nose, and throat; RA, rheumatoid arthritis; GU, urologic.
Table 6
Logistic regression modeling of risk factors for death in patients with Enterococcus
bacteremia (n = 652)
Factor OR (95% CI) p-Value
Charlson severity index 1.3 (1.2–1.4) <0.001
Solid organ transplant 0.1 (0.01–0.76) 0.027
E. faecalis isolate 0.44 (0.30–0.67) <0.001
Pulmonary infection 4.8 (2.2–10.2) <0.001
Polymicrobial infection 0.77 (0.50–1.2) 0.242
Nosocomial infection 2.15 (1.41–3.27) <0.001
OR, odds ratio; CI, conﬁdence interval.
E.O. Billington et al. / International Journal of Infectious Diseases 26 (2014) 76–82 81From this work it is apparent that of the two major Enterococcus
species, E. faecium is associated with a sicker subset of patients,
associated with higher rates of antimicrobial resistance and
ultimately mortality5,6,15. Furthermore, E. faecium BSI is associated
with a GI source, peptic ulcer disease, inﬂammatory bowel disease,
hematologic malignancy or bone marrow transplant. Conversely,
E. faecalis bacteremia is associated with a urinary tract source and
abnormal urinary tract anatomy. These results support the
consideration of E. faecalis and E. faecium as two different bacterial
entities, and suggest that more aggressive empiric antimicrobial
treatment of patients with enterococcal BSI.
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